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Allogeneic stem cell transplantation is an increasingly important treatment option in themanagement of adult
acute myeloid leukemia (AML). The major causes of treatment failure remain disease relapse and treatment
toxicity. In this review, Dr Vyas presents an overview of important recent data deﬁning molecular factors
associated with treatment failure in AML. He also identiﬁes the emerging importance of leukemia stem cell
biology in determining both response to therapy and relapse risk in AML. Dr Appelbaum discusses advances in
the design and delivery of bothmyeloablative and reduced-intensity conditioning regimens, highlighting novel
strategies with the potential to improve outcome. Dr Craddock discusses the development of both novel con-
ditioning regimens and post-transplantation strategies aimed at reducing the risk of disease relapse.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION augmentation of the antitumor activity of the conditioning
The advent of reduced-intensity conditioning (RIC) regi-
mens, coupled with expansion in alternative donor stem cell
sources, has dramatically increased the number of patients
with acute myeloid leukemia (AML) in whom allogeneic
transplantation can be considered a potential treatment
option. Given its attendant toxicity, the choice of which
patients have the potential to beneﬁt from an allograft now
assumes even greater importance. Advances in our under-
standing of the molecular determinants of disease relapse in
patients treated with conventional chemotherapy, coupled
with increased sophistication in predicting transplantation-
related mortality on the basis of both patient-donor HLA
disparity and comorbidity scoring are now routinely used to
inform such decision-making.
At the same time, it remains the case that a substantial
proportion of patients who proceed to transplantation are
destined to die of either procedure-related toxicity or disease
relapse. In this context, optimization of both patient selec-
tion and conditioning regimen design is central to improving
outcome. The challenge of reducing the risk of disease
relapse after allograft remains a particularly stubborn prob-
lem, but emerging and varied strategies focusing on eitheredgments on page 13.
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ty for Blood and Marrow Transplantation.regimen, without increasing its toxicity, or enhancement of a
graft-versus-leukemia (GVL) effect hold promise. Pivotal to
improving transplantation outcome will be the incorpora-
tion of advances in our understanding of the biology of dis-
ease relapse into transplantation schedules, coupledwith the
prospective assessment of novel treatment strategies in early
phase clinical trials and subsequently appropriately powered
randomized studies.
MOLECULAR AND CELLULAR DETERMINANTS OF
RELAPSE IN AML
The most common cause of death in treated patients with
AML is therapy-resistant disease. This review focuses on
relapse in patients with nonacute promyelocytic AML.
Approximately 50% of patients under the age of 60 and 90% of
patients over the age of 60with nonacute promyelocytic AML
relapse from initial therapy [1,2]. Despite enormous strides in
understanding the genetic basis of AMLand the importance of
the clinical relapse, it is remarkable how littlewe knowabout
the cellular and molecular mechanisms mediating therapy
resistance and, thus, relapse. The review will summarize
mature data on the AML mutational proﬁle prognostic of
relapse and discuss cellular heterogeneity in AML that may
also be important in therapy leading to relapse.
Genetic Markers Associated With Relapse
Our current understanding is that survival of AML
patients is dependent on patient-speciﬁc parameters
Table 1
European LeukemiaNET Genetic Prognostic Risk Groups
Genetic Risk Group Genetic Markers
Favorable t(8;21)(q22;q22); RUNX1-RUNX1T1
inv(16)(p13.1q22) or t(16;16)(p13.1;q22);
CBFB-MYH11
Mutated NPM1 without FLT3-ITD (CN-AML)
Bi-allelic mutation of CEBPA (CN-AML)
Intermediate-I Mutated NPM1 and FLT3-ITD (CN-AML)
Wild-type NPM1 and FLT3-ITD (CN-AML)
Wild-type NPM1 without FLT3-ITD (CN-AML)
Intermediate-II t(9;11)(p22;q23); MLLT3-MLL
Cytogenetic abnormalities not classiﬁed as
favorable or adverse
Adverse inv(3)(q21q26.2) or t(3;3)(q21;q26.2);
RPN1-EVI1.
t(6;9)(p23;q34); DEK-NUP214.
t(v;11)(v;q23); MLL rearranged.
5 or del(5q); 7; abnormal (17p).
Complex karyotype*
* Complex karyotype is deﬁned as 3 ormore chromosome abnormalities in
absence of World Health Organizationedesignated recurring translocations
or inversions: t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23),
t(6;9), inv(3), or t(3;3).
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the proﬁle of the pathogenetic driver genetic variants in the
AML. Investigators and trial groups have devised a number of
different prognostic risk groups from clinical and/or disease-
speciﬁc variables at diagnosis. One of the most widely used is
that devised by the European LeukemiaNET panel of experts
that divides AML into 4 prognostic risk groups (Table 1) [2].
The highest chance of achieving a complete remission
(CR) with intensive induction chemotherapy is in the
favorable-risk group (80% to 90% in patients under 60 years
of age and 70% to 80% in patients over the age of 60 years)
and the lowest chance of CR occurs in the adverse-risk group
(25% to 35%). Once a patient is in CR, the chance of relapse
varies depending on disease-speciﬁc cytogenetic and genetic
factors and the type of postinduction consolidation therapy
the patient receives. In general, European LeukemiaNET
favorable risk groups have the lowest risk of relapse (10% to
35%) and usually receive combination chemotherapy with or
without gemtuzumab ozogamicin monoclonal anti-CD33
antibody conjugated with calicheamicin [3]. Relapse is
highest in the adverse-risk group, where it varies from 70% to
90% with chemotherapy to 30% to 50% with myeloablative
(MA) transplantation.
Furthermore, within a risk category, coacquisition of
additional speciﬁc mutations inﬂuences prognosis and
relapse risk. Good examples of this are the increased relapse
risk with coacquisition of mutations in the KIT gene in core
binding factor (CBF) leukemia [4,5] and RUNX1 mutations in
normal karyotype AML [6,7]. However, the data are not so
clear in all situations. There are conﬂicting reports on the
impact of TET2 mutations in AML patients with normal cy-
togenetics and mutations in either NPM1 but wild-type for
FLT3 or in patients with bi-allelic mutations in CEPBA [8,9].
Thus, though we are beginning to understand how to use
genetic information together and we have an improved un-
derstanding of toxicity of therapies to develop risk-adapted
approaches to offer optimal postinduction consolidation
and decide who to offer transplantation [10], our under-
standing of markers of relapse are still rudimentary.
Recent whole genome (WGS) and exome sequencing
studies in diagnostic samples from de novo AML patients
have begun to illustrate the extent of molecularheterogeneity in AML. Analysis of 200 AML samples (50 by
WGS and 150 exomes) shows that 23 genes demonstrate a
higher than expected mutation prevalence in AML;
though, like most cancers, there is a much larger number
of genes (at least 1893) where mutations in coding regions
exist at low frequency and are predicted to cause signiﬁ-
cant change in protein function (tier 1 mutations) [11].
Further large-scale WGS studies (with deeper coverage)
and targeted resequencing studies are in progress or are
planned to validate mutation frequency and more accu-
rately deﬁne the frequency of rare mutations. As our un-
derstanding of the functional signiﬁcance of recurrent
acquired synonymous [12] and noncoding mutations in
RNA and regulatory elements [13] increases, we will gain a
deeper and more complete picture of the genetic
complexity of AML. Several of these studies are planned on
samples from large clinical trials with the potential to
reﬁne our current prognostic risk classiﬁcations. Eventu-
ally, these studies will have the potential to provide in-
formation on genetic variants that predict response to
speciﬁc therapies.
Any 1 AML sample has an average of 13 (range, 2 to 15)
tier 1 mutations, organized in at least 1 to 5 (average, 2)
different clones [11]. Although this raises the possibility of
an almost inﬁnite number of different clonal structures
across AML as a whole, as AML driver mutations are often
coselected, there are likely to be a more restricted number
of common clonal genotypes across the majority of patients
[11,14]. Given that the biologic behavior of AML cells is the
sum of all the acquired genetic changes, it is critical to
deﬁne clonal structures. This can be imputed by studies of
variant allele frequency (ie, clonal structures are inferred by
studying how common different mutations are) but is best
determined by extensive single-cell genotyping that
experimentally proves clonal composition. Such studies are
now just beginning in AML (Quek and Vyas, unpublished
data [15]).
Few studies have studied paired diagnostic and relapse
samples at a global genetic level to deﬁne how the genetic
composition of AML cells changes at relapse. The ﬁrst WGS
study of 8 paired samples showed that clonal evolution is
common at relapse and occurs through acquisition of new
mutations, either in the dominant founder clone or in a
subclone of the founder clone [16]. This study also high-
lighted the mutagenic effect of DNA-damaging chemo-
therapy. This raises the specter of therapy itself possibly
contributing to acquisition of therapy-resistant mutations.
Clonal evolution at relapse has also been documented by
single nucleotide polymorphism proﬁling and targeted
resequencing [17]. More WGS studies of paired samples in
similar or greater detail will be needed to understand if there
are speciﬁc patterns of clonal evolution for each initial clo-
notype and if they vary with therapies used.
Taking all the genetic variant data together, 2 remarkable
features emerge. First, all of the current data suggest that the
known genetic variants associated with higher rates of
relapse most likely function on the cell fate of the AML cell
itself (ie, on its quiescence, self-renewal, differentiation, and
proliferation properties) rather than how the cell deals with
therapy itself. If this is indeed true, it supports the notion that
most therapy does not tackle the underlying aberrant biology
of the AML cell itself. Second, the detailed mechanisms of
why any of the genetic markers associated with high relapse
rates (with the possible exception of TP53 mutation) cause
therapy failure remain obscure. Thus, a considerable amount
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therapy failure.
Functional Cellular Heterogeneity in AML
Seminal studies in AML (reviewed in [18]) have led to the
cancer stem cell hypothesis, which postulates that cancers
are organized in cellular hierarchies, as are normal tissues.
At the hierarchy apex are multipotent, largely quiescent,
long-lived cancer stem cells with marked self-renewal ca-
pacity that sustain disease and differentiate into “bulk
cancer cells.” A key experimental attribute of AML leukemic
stem cells (LSC) is that they are the only cell population
within AML that can serially propagate disease when
transplanted into immunodeﬁcient mice. This observation
raised the hypothesis that therapy may not need to eradi-
cate all AML cells, but only the leukemia-propagating AML
LSC. Furthermore, it has also been suggested that some
experimentally deﬁned AML LSC may be more chemo-
resistant, as they are more quiescent (being localized to a
protective bone niche environment) [19].
However, there are open questions about the biological
and clinical importance of experimentally AML LSC. First,
only w 50% to 60% of AML samples engraft in immunodeﬁ-
cient mice, suggesting that current murine models are not
ideally suited to propagate primary human AML and, thus,
detect leukemia-propagating populations. Second, even in
those primary samples that engraft, not all the clones seen in
a patient are able to engraft (Quek and Vyas, unpublished
data and [20]). Despite these important caveats, it is also
clear from global gene expression proﬁling that there are
marked differences in RNA composition between LSC and
non-LSC populations within a sample, suggesting that there
could be functional differences.
The clinical relevance of LSC still needs further investiga-
tion. Several studies have hinted that LSC populationsmay be
more therapy resistant and, thus, may potentially provide
important cellular markers of clinically relevant minimal re-
sidual disease (MRD) [21-24]. Furthermore, transcriptional
proﬁling studies have suggested that LSC-associated expres-
sion signatures are associatedwith a poorer outcome [25,26].
As bettermodels of interrogating primary human normal and
leukemic blood stem cell function are developed, some of the
scientiﬁc questions will be addressed. Furthermore, on going
large-scale studies to deﬁne the value of LSC quantitation as
an MRD marker and, thus, potentially important cell pop-
ulations to therapeutically target, will go someway to help us
understand the clinical importance of LSCs in relapse.
Finally, over the last 2 years, it has become clear that the
initiating mutations in both de novo [27-29] AML and AML
secondary to myelodysplasia (MDS) [30] occur in normal
hemopoietic stem cells and that this establishes a pre-
leukemic state. It is still unclear how commonly relapse
originates not only from a founder leukemic clone or sub-
lcone, but also from preleukemic clones. Studies over the
next few years will address this and, thus, establish whether
therapy needs to target not only leukemic clones but also
preleukemic clones.
CHOOSING A PREPARATIVE REGIMEN FOR PATIENTS
UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION FOR AML
A perfect preparative regimen for patients with AML
ndergoing allogeneic hematopoietic cell transplantation
would eliminate leukemia, provide adequate immunosup-
pression to guarantee engraftment, and have negligibletoxicity. Lacking perfection, we are forced to select among a
variety of imperfect choices. The following discussion
considers various trade-offs between regimens and how
these might be inﬂuenced by other factors, including graft-
versus-host disease (GVHD) and patient-speciﬁc variables.
Approaches to improve current regimens will also be
mentioned.
Dose Intensity and Disease Eradication
Either busulfan (Bu) or total body irradiation (TBI) is a
major component of most currently used preparative regi-
mens. With either agent, as doses increases, relapse rates
lessen, even at MA doses. A prospective randomized trial
performed almost 25 years ago found that increasing TBI
dosing from 12 Gy to 15.75 Gy reduced relapse rates from
35% to 12% in patients who underwent transplantation for
AML in ﬁrst remission [31]. Given the supportive care
measures available in the 1990s, mortality rates for patients
over age 60 or with serious comorbidities treated with MA
regimens were presumed to be unacceptably high, and so
regimens of reduced intensity that assured engraftment
were developed. There have been numerous retrospective
single-institution studies, including reports from Seattle,
Houston, and Boston, showing that these lower intensity
regimens, although effective in allowing older patients and
those with comorbidities to safely undergo transplantation,
are generally associated with higher relapse rates than seen
withmore intensive regimens [32-34]. In 2013, the European
Group for Blood and Marrow Transplantation reported re-
sults of a retrospective analysis involving 878 adults with
AML or MDS and found that relapse rate increased from 23%
with MA preparative regimens to 39% in RIC transplantations
[35]. They further reported that relapse rates were higher in
those receiving “minimal” RIC regimens (41%) than in those
receiving “intermediate” RIC regimens (22%). Most recently,
the Bone Marrow Transplant Clinical Trials Network closed
protocol 0901, a prospective randomized comparison of MA
versus RIC for patients with AML or MDS, after enrollment of
272 out of a planned 356 patients, because of an increased
relapse rate in the reduced-intensity arm.
The dose-response curves are not so steep that every
study has found a difference, particularly when the intervals
in dose intensity are small or when the numbers of patients
are limited. For example, in a retrospective study, the Boston
group reported little difference in relapse rates (54% versus
50%) when Bu doses were increased from 3.2 mg/kg to 6.4
mg/kg [36]. In a prospective study that was stopped early
because of poor accrual, the Dresden group did not ﬁnd a
difference in relapse rates between TBI doses of 8 and 12 Gy
[37]. But overall, the data seem convincing that when studied
over broad ranges, dose does make a difference.
Dose Intensity and Transplantation-related Toxicity
In the setting of ablative transplantations, although
higher dose TBI is associated with reduced relapse rates, it is
also associated with increased nonrelapse mortality (NRM).
Similarly, in the retrospective studies cited above,
comparing MA to RIC regimens, NRM rates tended to be
higher with higher dose regimens, especially during the
ﬁrst 100 days after transplantation [31,32,34,35,38]. In
general, higher dose regimens have been associated with
increased transfusion requirements, increased incidence of
idiopathic interstitial pneumonia and sinusoidal obstruc-
tion syndrome, and more bacterial infections [39-41].
However, the incidence of viral and fungal disease does not
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the preparative regimen [41].
Interaction of GVHD Prophylaxis and Preparative
Regimens
Preclinical studies have demonstrated that more inten-
sive preparative regimens result in a “proinﬂammatory
cytokine milieu” that favors the development of acute GVHD.
In fact, the very earliest randomized studies comparing 2
high-dose TBI regimens reported higher rates of acute GVHD
with the higher dose regimen [31]. When similar methods of
GVHD prophylaxis are used, acute GVHD and NRM are
increasedwithMA comparedwith RIC regimens [42]. Exactly
what proportion of the increased NRM seen after higher dose
regimens is due to direct organ damage versus how much is
contributed by the effects of GVHD is uncertain. Nonetheless,
the general principles seem clear: increasing intensity of the
preparative regimen results in more acute GVHD and a
higher rate of NRM. The obverse also seems likely; more
effective GVHD prophylaxis should result in less NRM and
may allow for an escalation in preparative regimen intensity
without an increase in NRM. When minimally intensive
preparative regimens, such as ﬂudarabine (Flu) 30 mg/m2/
day for 3 days plus 2 Gy TBI (Flu-TBI), are used, neither
antithymocyte globulin (ATG) nor T cell depletion are
commonly added because of concern for graft rejection.
When the intensity of the preparative regimen is increased,
such as with the use of Flu 30 mg/m2/days for 5 days plus Bu
4 mg/kg/day for 2 days, ATG can be added without a marked
increase in graft rejection (Flu-Bu-ATG). Blaise et al.
compared Flu-TBI versus Flu-Bu-ATG and found that the Flu-
Bu-ATG regimen was associated with a lower relapse rate, a
higher NRM, and equivalent overall survival [43]. That group
has since gradually increased the ATG dose from 2.5 mg/kg to
5 mg/kg with a further reduction in acute GVHD and NRM
and a seeming improvement in overall survival [44].
Increasing the ATG dose above 5 mg/kg in the setting of RIC
appears to result in an increased incidence of disease
recurrence, presumably due to loss of a GVL effect, which
may negatively impact overall survival [45,46]. There are
emerging data that more effective prevention of acute GVHD
may allow intensiﬁcation of the preparative regimenwithout
an increase in NRM. As 1 example, a very intensive prepar-
ative regimen used in the setting of T cell depletion includes
standard dose cyclophosphamide (Cy) (60 mg/kg  2) along
with high-dose TBI (1375 cGY) and thiotepa (5 mg/kg  2).
Although no randomized trial has yet been completed, a
retrospective comparison found no increase in NRM when
this regimen was compared with somewhat lower intensity
regimens delivered with conventional GVHD prophylaxis
[47]. As in the setting of RIC regimens, whether the increased
intensity afforded by improved GVHD control balances a
reduction in GVL is unknown.
Patient-speciﬁc Variables
For any given patient, the challenge is choosing the pre-
parative regimen that has the greatest likelihood of eradi-
cating malignancy without causing death or long-term
disability. Age is useful as a starting point but is an imperfect
surrogate for a patient’s ability to tolerate intensive therapy.
A pretransplantation assessment of mortality score has been
developed that provides a more accurate estimate of NRM
than age alone [48]. A second tool, the hematopoietic cell
transplantationespeciﬁc comorbidity index also aids in
predicting NRM [49]. Exercises have been conducted inwhich age and comorbidities have been used to predict NRM
after nonmyeloablative, RIC, and MA transplantation, and
have found that the combination of age and comorbidities
does a better job than either alone, but the predictions are
not perfect, suggesting that other factors are important [50].
We and others have found that individual variability in the
pharmacokinetics of Bu and Cy are associated with differ-
ences in transplantation-related toxicities [51,52]. These
differences are partly the result of polymorphisms in genes
responsible for drug metabolism and deposition. Likewise,
polymorphisms in selected histocompatibility genes have
been shown to associate with differences in GVHD risk [53].
Almost certainly, genetically determined differences in other
inﬂammatory and damage response pathways will be found
that predict tolerance to currently used preparative regi-
mens. Although current models do a reasonable job of pre-
dicting NRM after transplantation, one can easily imagine the
creation of better models that include genetic data as they
become better established. Nonetheless, the biggest risk
most patients undergoing transplantation for AML face is the
possibility of disease recurrence. Thus, in choosing among
preparative regimens, physicians must weigh the risk of
NRM carefully against the burden and biologic behavior of
the primary disease [54].
Alternative Agents
A number of alternatives to traditional preparative regi-
mens have been developed in the hopes of lessening toxicity
without sacriﬁcing antitumor effects. Intravenous Bu reduces
some of the pharmacologic variation seen with the oral drug
[55]. Flu has been used as a substitute for Cy in a number of
variations of the standard Bu-Cy regimens. A retrospective
matched-pair analysis found that NRMwas somewhat lower
with Flu-Bu comparedwith standard Bu-Cy, but relapse rates
were higher, resulting in no overall beneﬁt [56], and the only
prospective randomized trial comparing Flu-Bu with Bu-Cy
found that overall survival was superior with Bu-Cy [57].
Treosulfan is a prodrug of a bifunctional alkylating agent.
Several phase 2 studies have shown that combinations of
treosulfan with either Flu alone or Flu plus low-dose TBI are
well tolerated and result in excellent overall outcomes [58].
Currently, we and others continue to explore the use of
antibody targeted radio-immunotherapy as a way to deliver
higher dose radiation therapy to marrow, lymph nodes, and
other sites of disease without increasing toxicity to normal
organs. The results of phase 2 studies using an I131-labeled
antibody reactive with CD45 combined with Flu and TBI
have been very encouraging and a phase 3 trial is being
initiated [59].
Strategies to Prevent and Treat Relapse After Allograft
Disease relapse occurs in 30% to 80% of patients allog-
rafted for AML and represents the most common cause of
treatment failure [60]. At the same time, the outcome for
patients with recurrent disease after allograft remains
extremely poor [61,62]. Approaches with the potential to
reduce the risk of disease relapse include optimizing the
antitumor activity of the conditioning regimen without an
unacceptable increase in toxicity and the design of strategies
that optimize a GVL effect without increasing the risk of
GVHD.
Identiﬁcation of Patients at Risk of Relapse
Central to the design and rational deployment of strate-
gies with the potential to reduce relapse is a more accurate
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Disease-speciﬁc factors associated with an increased risk of
relapse include underlying disease biology, at both cytoge-
netic and molecular levels, and evidence of prior chemo-
resistance, as demonstrated by failure to achieve a CR after
the ﬁrst or second course of induction chemotherapy [63,64].
More recently, immunophenotypic evidence of residual
disease in patients who underwent transplantation in CR has
also been shown to be an important factor determining
relapse risk [65]. AML is a hierarchical disease originating
from a clonally transformed LSC cell and it has been hypoth-
esized that chemoresistant LSC serve as a reservoir of disease
in patients destined to relapse after both myelosuppressive
chemotherapy and epigenetic therapies [18,23,24]. There is,
however, a paucity of clinical studies addressing the impact of
stem cell transplantation on the LSC compartment. Such
studies will be important to assess whether quantitation of
this cellular population assists in risk stratiﬁcation of
transplantation-eligible patients as well as serves as a
biomarker of disease-free survival after allogeneic trans-
plantation.
Transplantation-speciﬁc factors, including both the use of
RIC regimens and augmented GVHD prophylaxis strategies
such as the use of in vivo T cell depletion, are also associated
with an increased risk of disease relapse. An integrated
analysis of the combined impact of leukemia-associated
somatic mutations and transplantation characteristics on
relapse risk in patients allografted for AMLwill be important,
as has recently been performed in patients allografted for
MDS [66]. The majority of patients destined to relapse after
an allogeneic transplantation for AML will do so within the
ﬁrst year after transplantation but a more precise charac-
terization of the factors determining the kinetics of disease
relapse is required if post-transplantation interventions are
to be optimally deployed.
Optimizing the Conditioning Regimen in High-risk AML
and MDS
A centrally important approach towards reducing relapse
risk is the design of both MA and RIC regimens that possess
augmented antitumor activity without a concomitant in-
crease in transplantation toxicity. The ameliorated toxicity of
an intravenous formulation of Bu has permitted the reﬁne-
ment of an MA Bu/Cy regimen [67]. At the same time, its
combination with the highly immunosuppressive purine
analogue, Flu, has resulted in the development of the
promising Flu/Bu regimen, both of which are currently under
evaluation in prospective trials. The extent to which the
antitumor activity of current RIC regimens differ was
revealed by a recent randomized trial in which patients with
a range of hematologic malignancies who underwent
transplantation using a Flu/Bu/ATG regimen demonstrated a
lower relapse rate than patients who received a Flu/low-dose
TBI regimen [43]. In light of the high relapse rates reported in
patients with high-risk AML using current RIC regimens, a
number of regimens with augmented antitumor activity
have been designed. Foremost among these is the FLAMSA
regimen, developed by the Munich group, that incorporates
both intensive pretransplantation cytoreduction and early
administration of donor lymphocyte infusions (DLI) [68].
Phase II studies in patients with poor-risk disease, specif-
ically AML in ﬁrst CR with adverse risk cytogenetics and
primary refractory disease, report a reduction in relapse risk
in this challenging population [69]. Recent studies suggest
that substitution of Bu for low-dose TBI, within the FLAMSAregimen, may further improve outcome and reduce trans-
plantation toxicity, particularly in patients over the age of 60
years. In separate studies, clofarabine, which possesses
additional antileukemic activity, has been combined with Bu
or melphalan with promising initial results. Encouraging
outcomes have also been reported using a combination of
Flu, melphalan, and BCNU [70,71]. The long-heralded po-
tential of adjunctive radioimmunotherapy to increase anti-
tumor effect without increasing toxicity is supported by the
observation that relapse risk is reduced in patients with very
higherisk AML whose conditioning regimen includes radi-
olabeled 131I-labeled anti-CD45 antibodies [72]. Despite this
proliferation of novel conditioning regimens, there are, to
date, no reports of the results of randomized trials in high-
risk AML patients and these must now be prioritized by the
transplantation community.Optimizing a GVL Effect in Patients Undergoing
Transplantation for High-risk AML
A potent GVL effect is evident in patients undergoing
transplantation for AML using either an MA or RIC regimen,
as evidenced by the inverse correlation between relapse risk
and both the occurrence of chronic GVHD and the intensity of
post-transplantation immunosuppression [73-75]. The
magnitude of this GVL effect presents a number of oppor-
tunities to reduce relapse risk, although the kinetics of dis-
ease relapse mandate early intervention. The duration and
intensity of post-transplantation immunosuppression rep-
resents an important and potentially manipulable determi-
nant of relapse risk. At present, however, the optimal
duration and dose of cyclosporin or tacrolimus administra-
tion in patients alllografted for high-risk AML remain un-
known and there remains considerable heterogeneity in
clinical practice.
Administration of DLI as a strategy to reduce relapse in
patients allografted for high-risk AML
Preemptive administration of DLI, guided by conventional
MRD assessments or LSC quantitation, represents an attrac-
tive strategy by which a GVL effect can be augmented in
patients deemed to be at a high risk of disease relapse.
Currently, a number of challenges are associated with
administration of DLI in high-risk patients undergoing
transplantation for AML. Because of the rapid kinetics of
disease relapse in AML, DLI must be delivered early, at a time
when it is associated with signiﬁcant GVHD-related
morbidity and mortality. This not only compromises its
clinical beneﬁt but also limits DLI dosing. In this context, the
emergence of biologically targeted drugs, such as tyrosine
kinase inhibitors and epigenetic therapies, which exert a
potent antitumor effect with limited hematopoietic toxicity,
presents an opportunity tomanipulate the kinetics of disease
relapse permitting the postponement of DLI to a time at
which it can be administered with less risk of toxicity. This
concept, by which GVHD and GVL might be dissociated, was
ﬁrst developed in the context of chronic myeloid leukemia,
where the administration of imatinib after transplantation
was shown to manipulate the kinetics of disease relapse
allowing the postponement of DLI administration [76] to a
time when it was associated with less toxicity. Building on
this model, the adjunctive administration of FLT3 inhibitors
and azacitidine in is of potential interest in patients with
AML deemed to be at a high risk of disease relapse after
transplantation [77].
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after transplantation
Pharmacological strategies aimed at augmenting a GVL
effect after transplantation have focused either on upregu-
lating the expression of putative target antigens on target
cells or manipulation of cellular effector function. DNA
methyltransferase (DNMT) inhibitors, such as azacitidine and
decitabine, upregulate the expression of both minor histo-
compatibility antigens and putative tumor antigens,
including members of the cancer testis antigen family. In
addition, prior exposure to these drugs augments killing of
tumor targets by CD8þ T cells [78]. At the same time, azaci-
tidine, possibly through demethylation of the Foxp3 pro-
moter, has the capacity to increase the number of circulating
regulatory T cells in murine transplantation models [79,80].
The possibility that epigenetic therapies such as azacitidine
might improve transplantation outcome by epigenetically
manipulating the alloreactive response has recently been
explored in patients undergoing a RIC allograft for high-risk
AML/MDS. Azacitidine is both well tolerated after trans-
plantation and appears to both accelerate regulatory T cell
reconstitution as well as induce a CD8þ T cell response to
candidate tumor antigens, presenting a novel strategy by
which both the risk of GVHD and disease relapse can be
reduced [81,82]. A number of other biological agents,
including histone deacetylase inhibitors and bortezomib,
modulate alloreactivity in animal models and present an
alternative strategy for improving outcome in patients
at high risk of disease relapse after transplantation. Lenali-
domide, because of its capacity to activate CD8þ T cells,
represents an alternative method of pharmacologically aug-
menting a GVL response after transplantation. Early phase
studies incorporating post-transplantation lenalidomide
have been complicated by a high-risk GVHD, conﬁrming its
ability to augment an alloreactive response after trans-
plantation [83]. However, given the excessive GVHD-related
toxicity associated with early lenalidomide admin-
istrationemodiﬁed treatment regimens, perhaps utilizing T
cell depletion or concurrent azacitidine administration are
required.
Management of Patients With Disease Relapse
Treatment options in patients who relapse after an
allogeneic stem cell transplantation for AML remain limited.
In patients with no evidence of active GVHD who relapse
more than 12 to 18 months after transplantation, a second
allograft can be produce long-term disease-free survival in a
proportion of patients, although there is no evidence that
use of a different stem cell donor is beneﬁcial [84]. DLI also
has the capacity to salvage a proportion of patients who
have achieved CR after salvage therapy [85]. The optimal
salvage regimen remains to be established. Conventional
myelosuppressive chemotherapy is associated with signiﬁ-
cant toxicity and there are emerging data that azacitidine,
with or without adjunctive DLI, may be an effective salvage
therapy [86].
CONCLUSION
Scientiﬁc advances in our understanding of the biology of
disease relapse after allogeneic stem cell transplantation
coupled with insights into how a GVL response be selectively
harnessed are pivotal to improving transplantation out-
comes in patients allografted for AML. At the same time, the
advent of novel conditioning regimens and biological agents
with the potential to manipulate the alloreactive responseafter transplantation present real opportunities to reduce
both transplantation toxicity and disease relapse. Integration
of biomarkers of response into well-designed early and late
phase prospective clinical trials remain the key to improving
patient outcome and mandate appropriate investment and
support by the wider transplantation community.ACKNOWLEDGMENTS
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